The drugs may help with joint and back pain, but doctors quoted by MarketWatch flag specific risks for older patients.
Recap by typeshit. Full story at MarketWatch.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Ro prescribes branded drugs like Zepbound and Wegovy but adds a membership on top of medication cost. People on Medicare or Medicaid can't join.
Medscape gives doctors guidance on getting GLP-1 coverage denials reversed for their patients. The full piece has the specifics.
Loading…